Reuters logo
BRIEF-Theravance biopharma highlights initiation of Phase 3 study
December 19, 2016 / 11:14 PM / 9 months ago

BRIEF-Theravance biopharma highlights initiation of Phase 3 study

Dec 19 (Reuters) - Theravance Biopharma Inc :

* Theravance Biopharma highlights initiation of phase 3 study of the closed triple in patients with asthma by glaxosmithkline and innoviva

* Theravance Biopharma Inc - additionally, theravance biopharma is not responsible for any costs related to closed triple

* Theravance Biopharma - should closed triple be approved, commercialized, co is entitled to receive an 85% economic interest in royalties paid by gsk on worldwide net sales Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below